Dyne Therapeutics
200 hedge funds and large institutions have $4.03B invested in Dyne Therapeutics in 2024 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 75 increasing their positions, 54 reducing their positions, and 34 closing their positions.
39% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 54
22% more call options, than puts
Call options by funds: $10.7M | Put options by funds: $8.75M
21% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 34
4% more funds holding
Funds holding: 193 → 200 (+7)
3% more capital invested
Capital invested by funds: $3.92B → $4.03B (+$117M)
1.42% less ownership
Funds ownership: 113.4% → 111.98% (-1.4%)
29% less funds holding in top 10
Funds holding in top 10: 14 → 10 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$148M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$87.1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$85.4M |
| 4 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$34.8M |
| 5 |
Man Group
London,
United Kingdom
|
+$28.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIS
FCPM III Services
Naarden,
Netherlands
|
-$75.3M |
| 2 |
Goldman Sachs
New York
|
-$56.7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$54.8M |
| 4 |
AG
Artal Group
Luxembourg
|
-$53.5M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$36.8M |
DYN Hedge Fund Activity: Q3 2024 in Review
200 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q3 2024, worth a combined $4.03B — up 3% from $3.92B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new DYN positions and 34 closed out — a net gain of 7 holders — while 75 added to existing stakes and 54 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $148M. The largest seller was FCPM III Services, cutting an estimated $75.3M.
- 200 institutional investors held Dyne Therapeutics (DYN) as of Q3 2024, up from 193 in Q2 2024.
- Funds reported $4.03B of Dyne Therapeutics stock for Q3 2024, up 3% quarter-over-quarter.
- 41 funds opened new Dyne Therapeutics positions in Q3 2024 and 34 closed out, a net change of +7 holders.
- The largest Dyne Therapeutics buyer in Q3 2024 was Fidelity Investments, an estimated $148M added.
- The largest Dyne Therapeutics seller in Q3 2024 was FCPM III Services, an estimated $75.3M sold.
Based on aggregated 13F filings for Q3 2024.